SEELOS THERAPEUTICS INC (SEEL)
US81577F3073 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.203M | 306K -86.11% | 28.968M 9,366.67% | 206.96M 614.44% | 258.92M 25.11% | 370.24M 42.99% | 438.58M 18.46% | 502.65M 14.61% | |||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -61.669M -228.74% | -70.916M -14.99% | -40.499M 42.89% | -36.618M 9.58% | -63.546M -73.54% | -31.824M 49.92% | 6.018M 118.91% | 73.746M 1,125.42% | 123.83M 67.91% | 126.28M 1.98% | |
| Operating Margin | N/A | N/A | -1,838.36% | -11,966.67% | -219.37% | -15.38% | 2.32% | 19.92% | 28.23% | 25.12% | |
| EPS YoY % growth | -0.75 -70.45% | -10.83 -1,344.00% | -45.32 -318.47% | -1.34 97.05% | -0.33 75.57% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -1.30 95.50% | -0.66 89.51% |
| Revenue Q2Q % growth | 76.5K -81.34% | 76.5K -88.28% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -10.541M 16.36% | -11.817M -47.51% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 81.61% | -1.21 | % | |
| Q1 2024 Q2Q % growth | 58.07% | -1.51 | % | |
| Q4 2023 Q2Q % growth | -6.32 -23.92% | -6.53 | 0.21 | 3.19% |
| Q3 2023 Q2Q % growth | -28.80 -433.33% | -14.69 | -14.11 | -96.08% |
| Q2 2023 Q2Q % growth | -6.60 -3,200.00% | -2.86 | -3.74 | -131.10% |
| Q1 2023 Q2Q % growth | -3.60 -2,669.23% | -3.37 | -0.23 | -6.95% |
| Q4 2022 Q2Q % growth | -5.10 -1,721.43% | -3.98 | -1.12 | -28.21% |
| Q3 2022 Q2Q % growth | -5.40 -4,809.09% | -3.21 | -2.19 | -68.07% |
| Q2 2022 Q2Q % growth | -0.20 -150.00% | -0.15 | -0.05 | -36.80% |
| Q1 2022 Q2Q % growth | -0.13 53.57% | -0.18 | 0.05 | 29.19% |
| Q4 2021 Q2Q % growth | -0.28 -115.38% | -0.11 | -0.17 | -149.55% |
| Q3 2021 Q2Q % growth | -0.11 -22.22% | -0.09 | -0.02 | -26.87% |
| Q2 2021 Q2Q % growth | -0.08 | -0.13 | 0.05 | 36.75% |
| Q1 2021 Q2Q % growth | -0.28 -100.00% | -0.09 | -0.19 | -205.01% |
| Q4 2020 Q2Q % growth | -0.13 51.85% | -0.08 | -0.05 | -59.31% |
| Q3 2020 Q2Q % growth | -0.09 30.77% | -0.08 | -0.01 | -10.29% |
| Q2 2020 Q2Q % growth | -0.08 11.11% | -0.14 | 0.06 | 41.90% |
| Q1 2020 Q2Q % growth | -0.14 89.93% | -0.22 | 0.08 | 37.61% |
| Q4 2019 Q2Q % growth | -0.27 | -0.17 | -0.10 | -60.43% |
| Q3 2019 Q2Q % growth | -0.13 | -0.12 | -0.01 | -6.21% |
| Q2 2019 Q2Q % growth | -0.09 97.00% | -0.13 | 0.04 | 32.13% |
| Q1 2019 Q2Q % growth | -1.39 66.90% | -0.18 | -1.21 | -657.08% |
| Q2 2018 Q2Q % growth | -3.00 | -3.67 | 0.67 | 18.30% |
| Q1 2018 Q2Q % growth | -4.20 | -3.67 | -0.53 | -14.38% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 376K 11.90% | 306K | 70K | 22.88% |
| Q1 2024 Q2Q % growth | 579K -28.34% | 306K | 273K | 89.22% |
| Q1 2023 Q2Q % growth | 808K | 204K | 604K | 296.08% |
| Q3 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | 0% | 0% | 0% | 0% |